Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
The median progression-free survival was 9.9 months (95% CI 6.7-12.1) in the standard group and 9.6 months (7.2-17.7) in the experimental group (HR of progression or death 0.78 [60% CI 0.65-0.93]; one-tailed p=0.085). Serious adverse events were reported more frequently in …
The median progression-free survival was 9.9 months (95% CI 6.7-12.1) in the standard group and 9.6 months (7.2-17.7) in the experimental gr …
Inhaler mishandling remains common in real life and is associated with reduced disease control.
Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, Serra M, Scichilone N, Sestini P, Aliani M, Neri M; Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri. Melani AS, et al. Respir Med. 2011 Jun;105(6):930-8. doi: 10.1016/j.rmed.2011.01.005. Epub 2011 Mar 2. Respir Med. 2011. PMID: 21367593 Free article.

Independently of the inhaler, we found the strongest association between inhaler misuse and older age (p = 0.008), lower schooling (p = 0.001) and lack of instruction received for inhaler technique by health caregivers (p < 0.001). Inhaler misuse was assoc

…
Independently of the inhaler, we found the strongest association between inhaler misuse and older age (p = 0.008), lower schooling ( …
C-reactive protein distribution and correlation with traditional cardiovascular risk factors in the Italian population.
Casula M, Tragni E, Zambon A, Filippi A, Brignoli O, Cricelli C, Poli A, Catapano AL; CHECK group. Casula M, et al. Eur J Intern Med. 2013 Mar;24(2):161-6. doi: 10.1016/j.ejim.2012.09.010. Epub 2012 Oct 4. Eur J Intern Med. 2013. PMID: 23040261
RESULTS: Median CRP (interquartile range) was higher in women (1.42 [0.58-2.86] vs 1.28 [0.58-2.50]; p=.163), in people aged 65 years (1.74 [0.89-3.34] vs 1.11 [0.52-2.45]; p<.001), in patients with obesity (2.37 [1.27-4.15] vs 1.16 [0.52-2.41]; p<.001) …
RESULTS: Median CRP (interquartile range) was higher in women (1.42 [0.58-2.86] vs 1.28 [0.58-2.50]; p=.163), in people aged 65 years …
Inhaler mishandling is very common in patients with chronic airflow obstruction and long-term home nebuliser use.
Melani AS, Canessa P, Coloretti I, DeAngelis G, DeTullio R, Del Donno M, Giacobbe R, Scarlato I, Serafini A, Barbato N, Vaghi A, Sestini P; Educational Study Group of the Italian Association of Hospital Pulmonologists (AIPO). Melani AS, et al. Respir Med. 2012 May;106(5):668-76. doi: 10.1016/j.rmed.2011.11.016. Epub 2012 Jan 25. Respir Med. 2012. PMID: 22277996 Free article.
Nebulisers users performed more critical inhalers errors than those of the OIU group (49% vs. 36%; p = 0.009). We conclude that our patients with CAO and regular nebuliser treatment had advanced age, severe respiratory conditions and common inhaler misuse....
Nebulisers users performed more critical inhalers errors than those of the OIU group (49% vs. 36%; p = 0.009). We conclude that our p …